Ptc Therapeutics (PTCT) Depreciation & Amortization (CF) (2012 - 2026)

Ptc Therapeutics' Depreciation & Amortization (CF) history runs 15 years deep, the most recent figure standing at $15.4 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 113.45% year-over-year to $15.4 million; the TTM figure through Mar 2026 stood at $47.0 million (up 71.0% YoY), while the FY2025 annual figure was $38.8 million, down 48.7% from the prior year.
• Depreciation & Amortization (CF) was $15.4 million for Q1 2026 at Ptc Therapeutics, up from $12.9 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $80.7 million in Q4 2023 to a low of $6.5 million in Q3 2024.
• Historically, Depreciation & Amortization (CF) has averaged $29.1 million across 5 years, with a median of $26.3 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) tumbled 91.62% in 2024, then soared 113.45% in 2026.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $38.9 million in 2022, then jumped by 107.65% to $80.7 million in 2023, then sank by 91.62% to $6.8 million in 2024, then jumped by 90.75% to $12.9 million in 2025, then rose by 19.46% to $15.4 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $15.4 million (Q1 2026), $12.9 million (Q4 2025), and $11.1 million (Q3 2025), per Business Quant data.